Adjuvant chemotherapy correlates with improved survival after radical cystectomy in patients with pT3b (macroscopic perivesical tissue invasion) bladder cancer

Journal of Cancer

Volumn 6, Issue 8, 2015, Pages 750-758

  Kim, Hyung Suk ^a   Piao, Songzhe ^a,b   Moon, Kyung Chul ^a   Jeong, Chang Wook ^a   Kwak, Cheol ^a   Kim, Hyeon Hoe ^a   Ku, Ja Hyeon ^a  

^a Seoul National University   (South Korea)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Perivesical tissue invasion; Radical cystectomy; Survival; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HAZARD RATIO; HUMAN; INDEPENDENT VARIABLE; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROTHELIAL CARCINOMA OF THE BLADDER;

EID: 84947790459     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.12259     Document Type: Article

References (25)

1. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234-241.
2. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778-792.
3. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999;161:1494-1497.
4. Frazier HA, Robertson JE, Dodge RK, Paulson DF. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1993;71:3993-4001.
5. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22:2781-2789.
6. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
7. Boudreaux KJ Jr., Chang SS, Lowrance WT, et al. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009;115:770-775.
8. Tilki D, Svatek RS, Karakiewicz PI, et al. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. J Urol. 2010;184:470-474.
9. Neuzillet Y, Lebret T, Molinie V, et al. Perivesical fat invasion in bladder cancer: implications for prognosis comparing pT2b, pT3a and pT3b stages and consequences for adjuvant chemotherapy indications. BJU Int. 2012;110:1736-1741.
10. Dincel C, Kara C, Balci U, et al. Comparison of microscopic (pT3a) and gross extravesical extension (pT3b) in pathological staging of bladder cancer: analysis of patient outcomes. Int Urol Nephrol. 2013;45:387-393.
11. Scosyrev E, Yao J, Messing E. Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology. 2010;76:908-913.
12. Karl A, Carroll PR, Gschwend JE, et al. The Impact of Lymphadenectomy and Lymph Node Metastasis on the Outcomes of Radical Cystectomy for Bladder Cancer. Eur Urol. 2009;55:826-835.
13. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Eng J Med. 2003;349:859-866.
14. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012;23:695-700.
15. Meeks JJ, Bellmunt J, Bochner BH, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012;62:523-533.
16. Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63:58-66.
17. Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: a population-based outcomes study. Cancer. 2014;120:1630-1638.
18. Raghavan D, Bawtinhimer A, Mahoney J, Eckrich S, Riggs S. Adjuvant chemotherapy for bladder cancer-why does level 1 evidence not support it? Ann Oncol. 2014;25:1930-1934.
19. Kim HS, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. The clinical significance of intraoperative ureteral frozen section analysis at radical cystectomy for urothelial carcinoma of the bladder. World J Urol. 2015;33:359-366.
20. Bolenz C, Herrmann E, Bastian PJ, et al. Lymphovascular invasion is an independent predictor of oncological outcomes in patients with lymph node-negative urothelial bladder cancer treated by radical cystectomy: a multicentre validation trial. BJU Int. 2010;106:493-499.
21. Hong SK, Kwak C, Jeon HG, Lee E, Lee SE. Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy? Urology. 2005;65:697-702.
22. Park J, Park S, Song C, et al. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy. Urology. 2007;70:257-262.
23. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66:42-54.
24. Yelfimov DA, Frank I, Boorjian SA, Thapa P, Cheville JC, Tollefson MK. Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World J Urol. 2014;32:1463-1468.
25. Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. The Cancer Journal. 2009;15:401-405.